Search Results
Your search for Matthew Stenger matches 7475 pages
Showing 1551 - 1600Telemedicine vs In-Person Postoperative Follow-up After Inpatient Oncologic Surgery
In a single-institution retrospective study reported in JCO Oncology Practice, Uppal et al found that telemedicine postoperative visits during the COVID-19 pandemic did not result in increased unplanned hospital readmissions vs in-person postoperative visits among patients undergoing elective...
Hyperthermic Intraperitoneal Chemotherapy With Primary or Interval Cytoreductive Surgery for Advanced Ovarian Cancer
In a Korean study reported in JAMA Surgery, Lim et al found that hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery did not improve progression-free survival vs no HIPEC in women with newly diagnosed stage III or IV epithelial ovarian cancer. A benefit of HIPEC was...
Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in JAMA Oncology, Li et al found that induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) prior to concurrent chemoradiation was associated with improved failure-free survival vs induction therapy with cisplatin and fluorouracil (PF) in...
Effect of Traditional Eligibility Criteria on Enrollment of Black Patients in Pancreatic Cancer Clinical Trials
In a single-center study reported in the Journal of Clinical Oncology, Riner et al found that traditional eligibility criteria for clinical trials in pancreatic ductal adenocarcinoma excluded a higher proportion of Black vs White patients and identified factors that commonly led to exclusion. As...
DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...
Association of Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy With Risk of Subsequent Peritoneal Carcinomatosis
Findings from a meta-analysis of individual patient data were reported in the Journal of Clinical Oncology. Steenbeek et al found that among women with BRCA1/2 pathogenic variants who underwent risk-reducing salpingo-oophorectomy for prevention of epithelial ovarian cancer, those with serous tubal...
Study Compares Surveillance Methods and Schedules in Stage I Testicular Seminoma
In the phase III TRISST trial reported in the Journal of Clinical Oncology, Joffe et al found that surveillance with magnetic resonance imaging (MRI) was noninferior to computed tomography (CT) in detecting advanced relapse in patients with stage I testicular seminoma who had undergone orchiectomy...
ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
As reported in The Lancet Oncology by Rebecca Kristeleit, MD, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations. Study...
Cabozantinib Plus Nivolumab in Advanced Non–Clear Cell Renal Cell Carcinoma
In a single-institution phase II study reported in the Journal of Clinical Oncology, Chung-Han Lee, MD, PhD, and colleagues found that the combination of cabozantinib and nivolumab was active in patients with advanced non–clear cell renal cell carcinoma (RCC) variants, particularly those with...
Transportation Barriers to Health Care Among Cancer Survivors in the United States
In a study reported in a research letter in JAMA Oncology, Changchuan Jiang, MD, MPH, and colleagues found that U.S. cancer survivors were more likely to report delays in health care due to transportation barriers than persons without a history of cancer, with the difference driven by barriers...
Long-Term Survival Outcomes With Adjuvant Capecitabine in Biliary Tract Cancer
As reported in the Journal of Clinical Oncology by Bridgewater et al, long-term follow-up of the phase III BILCAP study has shown a continued survival benefit with adjuvant capecitabine therapy in patients with curatively resected biliary tract cancer. In the multicenter trial, 447 patients with...
Thickness-Specific Incidence of Cutaneous Melanoma in the United States
In a population-based cohort study reported in JAMA Oncology, Chen et al found that the incidence of overall cutaneous melanoma and thinner tumors was stable in the United States from 2010 to 2018, with an increased incidence of the thickest (T4) melanomas being observed. Lower socioeconomic status ...
Risk of Colorectal Cancer May Be Linked to Cumulative Time With Excess Body Weight
In a German study reported in JAMA Oncology, Li et al found that assessment of risk of colorectal cancer based on cumulative lifetime excess weight may be more accurate than risk indicated by single body mass index (BMI) measurements. As stated by the investigators, “Excess weight is associated...
PD-1 Inhibition in Patients With Classic or Endemic Kaposi Sarcoma
In a French phase II study reported in The Lancet Oncology, Delyon et al found that pembrolizumab produced a high response rate in patients with classic or endemic Kaposi sarcoma with progressive cutaneous extension requiring systemic treatment. As stated by the investigators, “Although the...
Short-Term Radiotherapy Plus Preoperative Chemotherapy vs Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer
In the Chinese phase III STELLAR trial reported in the Journal of Clinical Oncology, Jin et al found that preoperative short-term radiotherapy followed by chemotherapy was not inferior in 3-year disease-free survival vs a standard schedule of long-term chemoradiotherapy in patients with locally...
Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers
In a study reported in the Journal of Clinical Oncology, David R. Freyer, DO, MS, and colleagues found that clinicians consistently undergraded—and caregivers frequently overgraded—the severity of adverse events experienced by children with cancer. Study Details The study included 438...
Study Evaluates Response-Based Immunotherapy Strategy in Patients With Advanced Urothelial Carcinoma
In a phase II study (TITAN-TCC) reported in the Journal of Clinical Oncology, Grimm et al found that a nivolumab/ipilimumab boost in patients with advanced urothelial cancer who did not respond to nivolumab monotherapy alone increased objective response rates, with the benefit being greatest in...
Oncologists’ Use of Geriatric Assessment Instruments in Older Patients With Cancer
In a study of a population of predominantly community-based oncologists reported in JCO Oncology Practice, Ajeet Gajra, MD, and colleagues found that a majority of oncologists surveyed did not use a formal geriatric assessment instrument to assist in treatment decisions for older patients with...
Guideline-Concordant Surgery and Adjuvant Chemotherapy for Early-Stage NSCLC
In a retrospective cohort study reported in JAMA Oncology, Kenneth L. Kehl, MD, MPH, and colleagues found that only a slight majority of patients with early-stage non–small cell lung cancer (NSCLC) who were enrolled in a U.S. screening study (ALCHEMIST) received guideline-recommended adequate lymph ...
Outcomes and Toxicity With Single-Agent Immune Checkpoint Inhibitor Treatment in Geriatric Patients With Cancer
In a multicenter international retrospective cohort study reported in JAMA Oncology, Caroline A. Nebhan, MD, PhD, of Vanderbilt University Medical Center, and colleagues found that single-agent immune checkpoint inhibitor therapy in patients with cancer aged 80 and older appeared to be effective...
Lu-177 Dotatate Plus Long-Acting Octreotide vs High‑Dose Long-Acting Octreotide in Midgut Neuroendocrine Tumors
As reported in The Lancet Oncology by Jonathan R. Strosberg, MD, of Moffitt Cancer Center, and colleagues, the final overall survival analysis of the phase III NETTER-1 trial has shown an approximately 12-month benefit with the addition of lutetium Lu-177 dotatate to long-acting octreotide in...
Observation vs Screening Spinal MRI in Patients With Castration-Resistant Prostate Cancer and Asymptomatic Spinal Metastases
As reported in The Lancet Oncology by David Dearnaley, FRCR, and colleagues, the phase III PROMPTS study has shown that a strategy of routine screening with spinal magnetic resonance imaging (MRI) and preemptive treatment to prevent clinical spinal cord compression is likely not warranted in...
Olaparib With or Without Cediranib vs Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
As reported in the Journal of Clinical Oncology by Joyce F. Liu, MD, and colleagues, the phase III NRG-GY004 trial has shown no significant improvement in progression-free survival with olaparib/cediranib vs platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer....
How Do Lifestyle and Cardiovascular Risk Factors Relate to Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors?
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, and colleagues identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors, finding that both incidence of hospitalization and risk of...
All-Cause Mortality After Adjuvant vs Early Salvage Radiation Therapy Following Radical Prostatectomy for pN1 Prostate Cancer
In a study in a German cohort reported in the Journal of Clinical Oncology, Tilki et al found that adjuvant radiation therapy was associated with reduced all-cause mortality vs early salvage radiation therapy after radical prostatectomy among men with pN1 prostate cancer. The benefit increased with ...
Characteristics of Nonalcoholic Fatty Liver Disease–Related HCC vs HCC From Other Causes
In a meta-analysis reported in The Lancet Oncology, Tan et al found that patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) were more likely to have metabolic/cardiovascular comorbidity, less likely to have cirrhosis, and less likely to undergo...
Early Intrathecal Therapy for High-Grade ICANS in Patients Receiving CAR T-Cell Therapy
In a single-institution retrospective review reported in JAMA Oncology, Zurko et al found that early intrathecal therapy with hydrocortisone with or without intrathecal chemotherapy was effective in treating grade ≥ 3 immune effector cell–associated neurotoxicity syndrome (ICANS) in patients...
Researchers Identify Trends in Treatment for Retroperitoneal Soft-Tissue Sarcoma
Researchers have published an analysis of strategies for treating retroperitoneal soft-tissue sarcoma, which has historically been understudied due to its rarity. The researchers say the trends they identified—particularly the convergence of certain treatments across centers—will help guide the way ...
Lung Cancer Diagnosis With Low-Dose CT Screening and a Program for Management of Incidentally Detected Lung Nodules
In the prospective observational DELUGE study reported in the Journal of Clinical Oncology, researchers in the Baptist Memorial Health Care Corporation (BMHCC) found that programs for low-dose computed tomography (CT) screening and for management of incidentally detected lung nodules were...
Perioperative Dose-Dense MVAC vs Gemcitabine/Cisplatin in Nonmetastatic Muscle-Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Pfister et al, the French phase III GETUG-AFU V05 VESPER trial showed a nonsignificant improvement in 3-year progression-free survival with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd- MVAC) vs gemcitabine/cisplatin given...
Temozolomide Followed by Low-Dose Ipilimumab/Nivolumab in MSS and MGMT-Silenced Metastatic Colorectal Cancer
In an Italian phase II study (MAYA) reported in the Journal of Clinical Oncology, Morano et al found that patients with microsatellite-stable (MSS) and O6-methylguanine–DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer without disease progression on temozolomide derived benefit...
Antibody Response to SARS–CoV-2 mRNA-1273 Vaccination in Patients With Cancer: Single-Institution Study
In a single-institution study reported in JAMA Oncology, Giuliano et al found that seroconversion after two doses of the SARS–CoV-2 mRNA-1273 (Moderna) vaccine in patients with cancer was lower among patients with hematologic malignancies vs solid tumors and differed according to cancer treatment...
Genetic Testing of Samples From Deceased Patients With Tubo-ovarian Cancer to Inform Families of Identification of Pathogenic Variants
As reported in the Journal of Clinical Oncology by Delahunty et al, an Australian pilot study of a genetic testing program (TRACEBACK) for deceased patients with tubo-ovarian cancer was successful in identifying pathogenic variants in samples from the patients, informing family, and engaging family ...
Trends in Grade 5 Toxicity and Response Rates in Phase I Trials for Hematologic Malignancies
In a study reported in the Journal of Clinical Oncology, Chihara et al found that rates of grade 5 toxicity have remained low and that rates of overall and complete response have increased over time in phase I trials for patients with hematologic malignancies sponsored by the National Cancer...
Addition of Ipatasertib to Abiraterone Plus Prednisolone Improves Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
In a phase III trial (IPATential150) reported in The Lancet, Christopher Sweeney, MD, of Dana-Farber Cancer Institute, and colleagues, found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in radiographic progression-free...
Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...
First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported inThe New England Journal of Medicine by Dean F. Bajorin, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo...
EV-301 Trial: Enfortumab Vedotin-ejfv Improves Overall Survival vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
As reported in The New England Journal of Medicine by Thomas Powles, MD, of Barts Cancer Centre, Queen Mary University of London, and colleagues, a prespecified interim analysis of the phase III EV-301 trial has shown improved overall survival with the antibody-drug conjugate enfortumab...
Sacituzumab Govitecan-hziy in Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy
In a cohort of the phase II TROPHY-U-01 trial reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, and colleagues, found that the antibody-drug conjugate sacituzumab govitecan-hziy produced durable responses in patients with metastatic...
Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors
In an English retrospective cohort study reported in JACC: CardioOncology, Strongman et al found that cardiovascular mortality in older cancer survivors ultimately exceeded mortality from common primary cancers in the time since their primary cancer diagnosis. However, the eventual predominance of...
Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplant: Analysis From 1981 to 2014
In an analysis from the BMT Survivor Study reported in the Journal of Clinical Oncology, Smita Bhatia, MD, MPH, and colleagues assessed late mortality over a 30-year period among patients who underwent autologous blood or marrow transplantation (BMT) for hematologic malignancies. They found an...
Addition of Bortezomib to Chemotherapy in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
As reported in the Journal of Clinical Oncology by Teachey et al, the phase III Children’s Oncology Group AALL1231 trial has shown that the addition of bortezomib to a modified augmented Berlin-Frankfurt-Münster (BFM) backbone improved survival outcomes in patients with newly diagnosed T-cell...
Thyroidectomy With or Without Radioiodine for Low-Risk Thyroid Cancer
In the French phase III ESTIMABL2 trial reported in The New England Journal of Medicine, Leboulleux et al found that no use of radioiodine was noninferior to radioiodine ablation in the occurrence of functional, structural, or biologic events among patients undergoing thyroidectomy for low-risk...
Racial Genomic Profiles of Primary and Metastatic Breast Cancer
In a study reported in a research letter in JAMA Network Open, Goel et al identified genomic differences among Black, Asian, and White patients with breast cancer and found that Black patients have fewer targetable actionable variants than White patients. Study Details The study included patients...
Factors Contributing to Racial Disparities in the Use of Prostate MRI in Older Patients With Prostate Cancer
In a study reported in JAMA Oncology, Michael S. Leapman, MD, and colleagues found that sociodemographic factors (like geographic area of residence) as well as manifestations of structural racism (like poverty and racial segregation) accounted for the majority of differences in the use of magnetic...
Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The New England Journal of Medicine by Gabriel N. Hortobagyi, MD, and colleagues, the protocol-specified final overall survival analysis of the phase III MONALEESA-2 trial has shown a significant benefit with the addition of ribociclib to letrozole in the first-line treatment of...
Cancer Risk Among Patients With Pediatric-Onset Inflammatory Bowel Disease
In a meta-analysis of population-based studies reported in JAMA Network Open, Elmahdi et al found that although the reported incidence of cancers in individuals with pediatric-onset inflammatory bowel disease (IBD) is low, the condition is associated with a significantly increased risk of cancers...
Intervention for Racial Disparities in Time to Lung Cancer Surgery: ACCURE Trial
In an analysis from the Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) trial reported in the Journal of Clinical Oncology, Marjory Charlot, MD, MPH, MSc, and colleagues found that the ACCURE intervention reduced the disparity between Black and White patients in time to...
Postoperative Weekly vs Every-3-Week Cisplatin in Chemoradiation for Locally Advanced Head and Neck Cancer
In a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Kiyota et al found that overall survival with once-weekly cisplatin in postoperative chemoradiation was noninferior to every-3-week cisplatin for patients with high-risk locally advanced squamous cell...
